Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) filed its monthly return for the period ended 30 April 2026, showing no movement in either registered or issued capital.

The company’s registered share capital remained at 364,588,000 ordinary H shares with a par value of RMB 1 each, equivalent to 364.59 million shares. No increase or decrease was recorded during the month.

Issued share data mirrored the registered figures: 364,588,000 shares were outstanding at both the beginning and end of April, and the company continued to hold zero treasury shares.

Biostar reaffirmed that it satisfies the Main Board’s minimum public-float threshold of 25 percent for its H-share class.

No share options, warrants, convertible securities, or other agreements to issue shares were outstanding or exercised in the reporting month.

The company highlighted that it had completed full circulation on 30 March 2026 by converting 147.87 million previously unlisted shares into H shares; this conversion did not affect April’s totals.

The monthly return was submitted by Company Secretary Chan Yik Pun on 6 May 2026.